Clinical trial
Antiproliferative Effect of Octreotide in Patients With Metastasized…
NCT00171873 · Carmen Schade-Brittinger, Other · Completed
Key facts
| NCT number | NCT00171873 |
|---|---|
| Title | Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut |
| Official title | Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut |
| Lead sponsor | Carmen Schade-Brittinger, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neuroendocrine Tumors |
| Intervention type | Drug |
| Interventions | Octreotide LAR (Long-acting release), Placebo |
| Enrollment | 85 |
| Start date | Sep 1, 2001 |
| Primary completion | Jun 1, 2008 |
| Completion | Dec 1, 2013 |
| First posted | Sep 15, 2005 |
| Last update posted | Mar 26, 2020 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: